Anacor Pharmaceuticals Reports Third Quarter 2011 financial Results MarketWatch (press release) We also successfully realized the End of state of matter 2 discussions with the FDA about our state of matter 3 development plans for AN2728 in psoriasis , and are on course to report Phase 2a data in atopic dermatitis by year-end. In addition, we amended and dilated our ... and more » Link To Article
No comments:
Post a Comment